NewAmsterdam Pharma Company NV
NAMS26.690USD
-0.040-0.15%
收盘 09/19, 16:00（美东）报价延迟15分钟
3.00B总市值
亏损市盈率 TTM
关于 NewAmsterdam Pharma Company NV 公司
NewAmsterdam Pharma Company NV 是一家荷兰公司。NewAmsterdam Pharma 是一家临床阶段公司，专注于研究和开发用于治疗主要心脏代谢疾病的变革性口服疗法。该公司正在研究 obicetrapib，一种口服、低剂量、每日一次的胆固醇酯转移蛋白 (CETP) 抑制剂，作为低密度脂蛋白胆固醇 (LDL-C) 降低疗法，用作高风险心血管疾病 (CVD) 患者的辅助他汀类药物疗法。该公司还在第二阶段 2 期试验 ROSE2 中测试 obicetrapib 与依折麦布的固定剂量联合疗法，用于治疗阿尔茨海默病等其他疾病。该公司致力于在全球范围内提供其产品。
公司简介
公司代码NAMS
公司名称NewAmsterdam Pharma Company NV
上市日期Nov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
员工数量68
证券类型Ordinary Share
年结日Nov 23
公司地址Gooimeer 2-35
城市NAARDEN
上市交易所NASDAQ Global Market Consolidated
国家Netherlands
邮编1411 DC
电话31352062971
网址https://ir.newamsterdampharma.com/
公司代码NAMS
上市日期Nov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月5日 周五
更新时间: 9月5日 周五
持股股东
股东类型
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
Forbion Capital Partners
9.39%
RA Capital Management, LP
9.00%
Capital World Investors
7.45%
其他
49.88%
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
Forbion Capital Partners
9.39%
RA Capital Management, LP
9.00%
Capital World Investors
7.45%
其他
49.88%
股东类型
持股股东
占比
Investment Advisor
29.13%
Investment Advisor/Hedge Fund
23.17%
Venture Capital
21.63%
Hedge Fund
15.00%
Private Equity
14.76%
Research Firm
1.68%
Family Office
0.74%
Sovereign Wealth Fund
0.44%
Individual Investor
0.44%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
2023Q1
105
62.44M
76.40%
-1.21M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
16.12M
14.36%
+200.00K
+1.26%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.55%
--
--
Mar 31, 2025
Forbion Capital Partners
10.66M
9.49%
-279.14K
-2.55%
Apr 15, 2025
RA Capital Management, LP
10.14M
9.03%
+1.29M
+14.63%
Mar 31, 2025
Capital World Investors
6.80M
6.06%
+5.78M
+569.10%
Mar 31, 2025
Viking Global Investors LP
6.98M
6.22%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
4.10M
3.66%
-210.38K
-4.88%
Mar 31, 2025
Wellington Management Company, LLP
3.54M
3.15%
+1.23M
+52.99%
Mar 31, 2025
Adage Capital Management, L.P.
1.95M
1.74%
+900.65K
+85.78%
Mar 31, 2025
Jennison Associates LLC
3.97M
3.54%
-28.35K
-0.71%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
ALPS Medical Breakthroughs ETF
1.47%
Global X Guru Index ETF
1.45%
Virtus LifeSci Biotech Clinical Trials ETF
1.23%
Invesco Dorsey Wright SmallCap Momentum ETF
0.41%
ProShares Ultra Nasdaq Biotechnology
0.27%
Invesco Nasdaq Biotechnology ETF
0.24%
iShares Biotechnology ETF
0.14%
First Trust IPOX Europe Equity Opportunities ETF
0.08%
SPDR S&P International Small Cap ETF
0.07%
Strive Small-Cap ETF
0.07%
查看更多
ALPS Medical Breakthroughs ETF
占比1.47%
Global X Guru Index ETF
占比1.45%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.23%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.41%
ProShares Ultra Nasdaq Biotechnology
占比0.27%
Invesco Nasdaq Biotechnology ETF
占比0.24%
iShares Biotechnology ETF
占比0.14%
First Trust IPOX Europe Equity Opportunities ETF
占比0.08%
SPDR S&P International Small Cap ETF
占比0.07%
Strive Small-Cap ETF
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
